CompletedPhase 1NCT02445963
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
Studying Shigellosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- U.S. Army Medical Research and Development Command
- Principal Investigator
- Christopher Duplessis, MD, MPH, MSEnteric Diseases Department Naval Medical Research Center
- Intervention
- Shigella flexneri 2a InvaplexAR(biological)
- Enrollment
- 38 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2015 – 2016
Study locations (1)
- Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02445963 on ClinicalTrials.govOther trials for Shigellosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07433426The Impact of Shigellosis and Recommended Treatment in ChildrenJohns Hopkins Bloomberg School of Public Health
- RECRUITINGPHASE1NCT05959616Shigella Sonnei 53G Human Infection Study in Kenyan AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT06615375A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineLimmaTech Biologics AG
- RECRUITINGPHASE1NCT05961059InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and ZambiaLeiden University Medical Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05182749Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of ShigellosisIntralytix, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05121974Tebipenem Trial in Children With ShigellosisInternational Centre for Diarrhoeal Disease Research, Bangladesh